步长制药：泸州步长拟授权Helios在目标区域内完成注射用Efparepoetin alfa的独家营销和经销

Core Viewpoint - The company has signed a distribution, marketing service, and agency agreement with Helios and Zaoan International for the exclusive marketing and distribution of injectable Efparepoetin alfa in targeted regions, which is a new Class I biopharmaceutical drug for treating anemia in adult dialysis patients due to chronic kidney disease (CKD) [1] Group 1 - The subsidiary Luzhou Buchang will authorize Helios to carry out exclusive marketing and distribution of injectable Efparepoetin alfa [1] - Injectable Efparepoetin alfa is intended for adult dialysis patients undergoing erythropoietin therapy due to anemia caused by chronic kidney disease [1] - The drug has already submitted a market application for approval [1]